Stratec's prosthetics sales hit by strategy change:
This article was originally published in Clinica
Sales in Stratec's prosthetics business were SwFr50 million ($34 million) in 1998, compared with SwFr59 million in the previous year. The drop in sales resulted from the company's strategy to manufacture and market its own prosthetic products. Oberdorf-based Stratec says the business grew 8% in the second half, partly making up for the 27% drop in the first half. However, sales in Stratec's core business, osteosynthesis, were SwFr215 million in 1998, up 7% on the previous year, above the market rate. The spinal business performed particularly well, the company says. Total sales were SwFr265 million, up 2% on the previous year.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.